Insiders · DFTX

DFTX insider transactions

Definium Therapeutics Inc. (DFTX) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for DFTX

• 1d
  Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 24% to 513,317 units (SEC Form 4)

  4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
• 1d
  Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 50% to 1,127,454 units (SEC Form 4)

  4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
• 1d
  Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 23% to 333,579 units (SEC Form 4)

  4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
• 1d
  Chief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 42% to 212,500 units (SEC Form 4)

  4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
• 1d
  Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 54% to 177,500 units (SEC Form 4)

  4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
• 7d
  Director Vallone Carol A was granted 4,666 shares, increasing direct ownership by 28% to 21,210 units (SEC Form 4)

  4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
• 7d
  Director Crystal Roger was granted 4,666 shares, increasing direct ownership by 24% to 24,289 units (SEC Form 4)

  4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
• 7d
  Director Gryska David W was granted 4,666 shares, increasing direct ownership by 31% to 19,900 units (SEC Form 4)

  4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
• 7d
  Director Adsett Roger was granted 3,555 shares (SEC Form 4)

  4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
• 7d
  Director Krebs Andreas was granted 4,666 shares, increasing direct ownership by 31% to 19,773 units (SEC Form 4)

  4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
• 7d
  Director Bruhn Suzanne Louise was granted 4,666 shares, increasing direct ownership by 24% to 24,289 units (SEC Form 4)

  4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
• 88d
  SEC Form 4 filed by Karlin Daniel

  4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
• 88d
  SEC Form 4 filed by Sullivan Mark

  4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
• 88d
  SEC Form 4 filed by Barrow Robert

  4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
• 137d
  Chief Commercial Officer Wiley Matthew T. was granted 115,000 shares (SEC Form 4)

  4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
• 137d
  Chief Financial Officer Roberts Brandi was granted 150,000 shares (SEC Form 4)

  4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
• 137d
  Chief Legal Officer Sullivan Mark was granted 125,000 shares, increasing direct ownership by 44% to 407,576 units (SEC Form 4)

  4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
• 137d
  Chief Medical Officer Karlin Daniel was granted 150,000 shares, increasing direct ownership by 35% to 575,025 units (SEC Form 4)

  4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
• 137d
  Chief Executive Officer Barrow Robert was granted 320,000 shares, increasing direct ownership by 41% to 1,098,477 units (SEC Form 4)

  4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
• 144d
  SEC Form 4 filed by Director Adsett Roger

  4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
• 144d
  SEC Form 3 filed by new insider Adsett Roger

  3 - Definium Therapeutics, Inc. (0001813814) (Issuer)